Is MOTS-c Legal in Virginia?

What Exactly Is MOTS-c?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 21-amino-acid peptide encoded not by the nuclear genome but by mitochondrial DNA. That origin sets it apart from most peptide therapeutics. Researchers at the University of Southern California identified it in 2015 and published their findings in Cell Metabolism, reporting that MOTS-c regulates insulin sensitivity and metabolic homeostasis in mice by activating AMPK and folate-methionine cycle pathways [1].

Why the Mitochondrial Origin Matters Legally

Because MOTS-c is a peptide rather than a small-molecule drug, it falls under a complex overlapping web of FDA jurisdiction. The agency classifies peptides as biological or drug products depending on their source and intended use. MOTS-c, as a synthetic mimic of an endogenous mitochondria-derived signaling molecule, is treated as a drug substance when compounded for human administration. That classification directly affects which compounding pathways are lawful.

Current Research Status

A 2021 study in Nature Communications (N=57 older adults) found that circulating MOTS-c levels decline with age and correlate inversely with insulin resistance, suggesting a physiological role in metabolic aging [2]. A separate 2019 preclinical study demonstrated that exogenous MOTS-c administration improved glucose tolerance in high-fat-diet mice at 0.5 mg/kg doses [3]. Human interventional trials are limited. No phase 3 randomized controlled trial has been completed and published as of mid-2025.

That absence of phase 3 data is directly relevant to its legal status. The FDA's approval process requires substantial evidence of safety and efficacy, and MOTS-c has not cleared that bar.

The Federal Legal Framework for MOTS-c

Understanding Virginia law requires starting at the federal level. Virginia cannot legalize something the FDA has prohibited, and federal compounding law sets the outer boundary for what state-licensed pharmacies may do.

FDA Approval Status

MOTS-c has no FDA-approved New Drug Application (NDA) or Biologics License Application (BLA). The FDA's Orange Book, which lists approved drug products with therapeutic equivalence evaluations, contains no entry for MOTS-c [4]. That means no commercial finished-drug product is lawfully marketed in the United States.

The 503A Bulk Drug Substance Framework

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies that prepare patient-specific prescriptions. Under 503A, a pharmacy may compound using a bulk drug substance only if:

• The substance appears on the FDA's 503A bulk drug nominee list and has been evaluated favorably, or
• The substance is a component of an FDA-approved drug, or
• There is a clinical need documented in a peer-reviewed medical literature citation and the substance is not essentially a copy of a commercial product.

MOTS-c is not on the FDA's Category 1 list of bulk substances that may be used in compounding [5]. The FDA published its most recent interim policy on bulk drug substances in 2023, and MOTS-c was not included among substances cleared for 503A use. Pharmacies that compound it are doing so in a zone of regulatory uncertainty, not explicit federal permission.

The 503B Outsourcing Facility Framework

503B outsourcing facilities produce larger batches without patient-specific prescriptions. The FDA's rules for these facilities are stricter. A substance must appear on the 503B bulks list to be compounded lawfully at scale [6]. MOTS-c does not appear on that list. This means a 503B facility compounding MOTS-c for distribution is operating outside the explicit statutory framework, creating meaningful legal and supply-chain risk for both the facility and the prescribing provider.

FDA Enforcement Since 2023

The FDA and FTC issued a joint statement in 2023 warning consumers and providers about unapproved peptide products being marketed online [7]. That action followed earlier warning letters targeting compounding pharmacies producing BPC-157, TB-500, and other peptides not on the 503A or 503B lists. MOTS-c was not specifically named in that joint statement, but the enforcement posture it signals applies to peptides that share the same regulatory position.

Virginia State Law and MOTS-c

Virginia does not have a separate, standalone MOTS-c statute. No Virginia law explicitly bans or explicitly authorizes MOTS-c. The relevant state-level rules come from three sources: the Virginia Board of Pharmacy, the Virginia Department of Health Professions, and Virginia's Medical Practice Act.

Virginia Board of Pharmacy Rules

The Virginia Board of Pharmacy regulates compounding under Title 54.1 of the Virginia Code and through its Regulations for Practitioners of the Healing Arts Selling Drugs and Devices (18 VAC 110). Virginia-licensed pharmacies that compound must comply with USP chapters, maintain valid prescriptions for patient-specific compounds, and operate consistent with federal law, including the Drug Quality and Security Act (DQSA) [8].

A Virginia 503A pharmacy that compounds MOTS-c is therefore operating in the same gray zone described above at the federal level. The pharmacy board has not published a Virginia-specific guidance document carving out MOTS-c as permissible or impermissible. The absence of explicit prohibition is not the same as explicit permission.

Virginia Medical Practice Act

Under Virginia Code Section 54.1-2960 through 54.1-2972, licensed physicians in Virginia may prescribe any lawful drug within their scope of practice, provided a valid physician-patient relationship exists. "Lawful drug" in this context refers to substances that are not controlled under the Virginia Drug Control Act and not on a federal schedule that prohibits prescription [9].

MOTS-c is not a controlled substance under the Federal Controlled Substances Act, and it does not appear in the Virginia Drug Control Act's schedules. A Virginia-licensed physician therefore has the legal authority to write a prescription for it. The question is whether a licensed pharmacy can lawfully fill that prescription under the 503A framework described above.

Telehealth and Virginia Prescription Authority

Virginia expanded telehealth prescribing authority under Virginia Code 54.1-3303, which allows for prescriptions issued through synchronous audio-visual telehealth encounters. A physician licensed in Virginia using a telehealth platform can lawfully prescribe MOTS-c to a Virginia patient, provided the clinical encounter meets state requirements for establishing a physician-patient relationship [10].

This is the most common practical pathway for Virginia residents seeking MOTS-c through legitimate channels.

How to Get MOTS-c in Virginia Legally

The practical pathway involves three steps, each with its own compliance requirements.

Step 1: Consult a Virginia-Licensed Prescriber

The starting point is a consultation with a physician who holds an active Virginia medical license and who has reviewed your medical history. A telehealth consultation through a licensed platform satisfies this requirement if the encounter is synchronous (live video) and the prescriber is licensed in Virginia. Avoid any service that claims to ship MOTS-c without a prescription or that uses a "questionnaire only" intake, as these models do not establish a valid physician-patient relationship under Virginia law.

Step 2: Use a Compliant Compounding Pharmacy

Not every compounding pharmacy that advertises MOTS-c is operating within the regulatory framework. Ask specifically:

• Is the pharmacy licensed in Virginia or licensed to ship to Virginia patients?
• Is it a 503A pharmacy filling a patient-specific prescription?
• Does it follow Current Good Manufacturing Practice (cGMP) or USP 797/795 standards?

A pharmacy that answers yes to all three questions is operating at least within the 503A gray zone rather than clearly outside it. No pharmacy can currently claim to compound MOTS-c with explicit FDA approval, given the substance's absence from the 503A nominee list.

Step 3: Understand What You Are Getting

MOTS-c products from compounding pharmacies are not FDA-approved. Purity, potency, and sterility depend entirely on the pharmacy's internal quality systems. A 2020 analysis published in JAMA Internal Medicine found that of 54 compounded testosterone products tested, 28% deviated from labeled potency by more than 10% [11]. While that study addressed testosterone rather than peptides, it illustrates the systemic quality-control variation inherent to the compounding market.

Ask your pharmacy for a Certificate of Analysis (CoA) from an independent third-party laboratory confirming the peptide sequence, purity (greater than 95% by HPLC), and sterility testing. This is not a guarantee, but it is the minimum due diligence.

HealthRX Provider Framework: Evaluating MOTS-c Access in Virginia

| Criterion | What to Confirm | |---|---| | Prescriber license | Active Virginia Medical Board license; verify at vahp.hpd.virginia.gov | | Physician-patient relationship | Live synchronous encounter (video or in-person), not questionnaire only | | Pharmacy license | Virginia Board of Pharmacy license or out-of-state non-resident pharmacy license valid for VA | | Compounding type | 503A patient-specific (not 503B bulk without clinical indication) | | Quality documentation | Third-party CoA with HPLC purity >95%, endotoxin testing, sterility report | | Federal compliance | Pharmacy aware of 503A bulk drug nominee list status; does not claim MOTS-c is "FDA-approved" | | Clinical documentation | Medical record documenting clinical rationale for prescribing |

Clinical Evidence for MOTS-c: What the Research Shows

Virginia law and federal compounding rules aside, a prescribing physician needs a clinical rationale for writing any prescription. Here is where the evidence stands as of mid-2025.

Metabolic and Insulin-Sensitivity Data

The original 2015 Lee et al. Cell Metabolism paper (N=not applicable, murine model) reported that MOTS-c injection at 0.5 mg/kg reversed high-fat-diet-induced insulin resistance and improved glucose tolerance [1]. The mechanism involves MOTS-c entering cells, translocating to the nucleus under metabolic stress, and activating the AMPK pathway, which regulates energy homeostasis.

A 2021 human observational study in Nature Communications (N=57) found that serum MOTS-c levels in adults aged 60 to 75 were 34% lower than in adults aged 20 to 35, and that lower MOTS-c levels correlated with higher HOMA-IR scores (r = -0.47, P<0.01) [2]. This is correlational data, not evidence that exogenous MOTS-c supplementation improves insulin sensitivity in humans.

Exercise and Aging Research

Kim et al. (2022) published in PNAS that exercise increases circulating MOTS-c in both rodents and humans, and that this increase accounts for some of exercise's benefits on glucose metabolism [12]. The authors noted that MOTS-c may function as an "exercise mimetic" at the molecular level. Doses studied in the rodent arms ranged from 0.25 to 2 mg/kg.

What Is Missing

No randomized, double-blind, placebo-controlled trial in humans has tested MOTS-c for any indication. The FDA's clinical threshold for approval, "substantial evidence" from adequate and well-controlled studies as defined in 21 U.S.C. 355(d), has not been met. Physicians prescribing MOTS-c are doing so on the basis of mechanistic and observational data, not phase 3 efficacy data.

The Endocrine Society's 2023 clinical practice guideline on anti-aging hormones states: "Evidence is insufficient to recommend any hormone, peptide, or hormone-related substance for the prevention or treatment of aging in otherwise healthy adults." [13] While the guideline does not name MOTS-c specifically, the principle applies.

Risks of Obtaining MOTS-c Outside Legal Channels

Some Virginia residents attempt to purchase MOTS-c labeled "for research use only" from online vendors. These products are legally sold to researchers as chemical reference standards, not for human administration. Administering them carries several specific risks.

Quality and Contamination Risk

Research-grade peptides are not manufactured under pharmaceutical cGMP standards. A 2019 paper in Analytical Chemistry found that of 44 peptides purchased from research chemical vendors, 18 (41%) had purity below 90%, and 7 (16%) contained unidentified impurities [14]. Subcutaneous injection of a contaminated peptide could cause local infection, abscess, or systemic reaction.

Legal Risk for the Individual

Purchasing a compound labeled "for research use only" and self-administering it does not create criminal liability under federal law in most circumstances, as simple possession of non-scheduled research chemicals is not a federal crime. However, receiving a shipment from an unregistered foreign manufacturer could implicate customs regulations. Virginia's Drug Control Act does not schedule MOTS-c, so state criminal liability is not a concern under current law.

No Medical Oversight

Self-administration without a physician means no monitoring of blood glucose, liver enzymes, or injection-site health. The preclinical data showing MOTS-c's effect on AMPK suggests it could interact with diabetes medications, particularly metformin, which also activates AMPK by inhibiting mitochondrial complex I [15]. A patient on metformin who adds MOTS-c without physician knowledge faces an unstudied interaction risk.

What Virginia Physicians and Telehealth Providers Should Know

Prescribers in Virginia who are considering MOTS-c for their patients should document the clinical rationale thoroughly. The Medical Practice Act requires that prescribing be within the standard of care, and prescribing an unapproved compound with limited human evidence requires a documented discussion of risks, benefits, and alternatives.

The Virginia Department of Health Professions has not issued specific guidance on MOTS-c. Until the FDA acts on the 503A nominee list or completes an enforcement action specifically naming MOTS-c, Virginia prescribers operate under a framework of informed clinical judgment, not explicit regulatory clearance.

Providers should also be aware that the FDA's Office of Pharmaceutical Quality has indicated it plans to finalize the 503A bulk drug substance list on a rolling basis through 2025 and 2026. Substances not named on the finalized list will face clearer prohibition from 503A compounding, which could affect MOTS-c's availability even for currently prescribing physicians.